HC Wainwright Reaffirms “Buy” Rating for CG Oncology (NASDAQ:CGON)

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research report released on Tuesday,Benzinga reports. They currently have a $75.00 price objective on the stock.

Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada restated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. Morgan Stanley restated an “overweight” rating and issued a $55.00 price target on shares of CG Oncology in a research report on Friday, March 7th. Finally, TD Cowen started coverage on shares of CG Oncology in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, CG Oncology has a consensus rating of “Buy” and an average target price of $63.88.

CG Oncology Stock Performance

Shares of NASDAQ:CGON opened at $27.54 on Tuesday. The business has a 50 day moving average price of $28.07 and a 200 day moving average price of $32.01. CG Oncology has a twelve month low of $23.91 and a twelve month high of $46.99.

Insider Buying and Selling

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Institutional Investors Weigh In On CG Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. NEOS Investment Management LLC lifted its position in shares of CG Oncology by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 8,329 shares of the company’s stock worth $239,000 after purchasing an additional 817 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CG Oncology by 3.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,080 shares of the company’s stock worth $862,000 after purchasing an additional 1,026 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in CG Oncology during the 4th quarter worth $41,000. Rhumbline Advisers lifted its holdings in CG Oncology by 2.2% during the 4th quarter. Rhumbline Advisers now owns 69,016 shares of the company’s stock worth $1,979,000 after buying an additional 1,458 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in CG Oncology by 16.4% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,834 shares of the company’s stock valued at $368,000 after buying an additional 1,810 shares during the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.